Free survival of patients disease free survival. Medical search. Frequent questions

An independent, central radiology review board assessed disease progression and tumor shrinkage. (amgen.com)
Patients who received panitumumab every two weeks showed a 46 percent decrease in tumor progression rate versus those who received best supportive care alone (p less than 0.000 000 001). (amgen.com)
The rate (75 percent) and timing (median 7.0 weeks) of crossover from the BSC alone arm to receiving panitumumab, and the anti-tumor activity observed after crossover, likely confounded the ability to demonstrate a treatment effect on overall survival (Hazard ratio = 0.93). (amgen.com)
Improvements in progression-free survival and disease control also occurred regardless of age, sex, primary tumor location (colon versus rectum), or performance status. (amgen.com)
Significant parameters used in the determination of the prognosis and survival of esophageal cancer include tumor stage, surgical margin, and metastatic lymph node status. (researchsquare.com)
Accumulating evidence shows that in addition to the characteristics of the tumor, the immune response of the patient is also highly important for determining the prognosis. (researchsquare.com)
The objective of this prospective study was to assess the prognostic impact of isolated tumor cells (ITC, defined as cell deposits ≤ 0.2 mm) in loco-regional LN of stage I & II colon cancer patients. (biomedcentral.com)
Those high-risk stage II colon cancer patients feature at least one of the follwing characteristics: pT4 tumor, poorly differentiated histology, presence of lymphovascular invasion, localized perforation, bowel obstruction or less than 12 lymph nodes (LN) analyzed [ 4 , 6 ]. (biomedcentral.com)
Background: This study aimed to determine the relationship between the pre-operative metabolic tumor volume (MTV) and the disease-free survival (DFS) of patients with stage I non-small cell lung cancer (NSCLC) using F-18 2-fluoro-2-deoxy-D-glucose (FDG) positron-emission tomography-computed tomography (PET-CT) scanning. (iiarjournals.org)
Recently, two investigators suggested that certain parameters measured using F-18 2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography and computed-tomography (PET-CT), such as the maximal standard uptake value (SUVmax), the metabolic tumor volume (MTV), and the total lesion glycolysis, were associated with clinical outcome of patients with advanced NSCLC ( 6 , 7 ). (iiarjournals.org)
In this context, there is a need for new predictive markers, beyond the tumor stage, to select what patients will benefit from an adjuvant treatment and to better tailor treatment schemes and schedules. (frontiersin.org)
Patients typically seek treatment when symptoms, which usually involve pain only at the site of the tumor, persist. (medscape.com)
AP2S1 , P3H4 , and RAC3 were identified as candidate tumor-specific antigens, and patients with the BCS2 and BCS1A subtypes were identified as candidate populations for mRNA vaccines. (frontiersin.org)
tumor size and EHD1 expression of osteosarcomas were independent prognostic indicators of OS in osteosarcoma patients. (biomedcentral.com)
The expression of EHD1 in tumor and normal tissues collected from 57 osteosarcoma patients was measured using immunohistochemistry techniques, and correlations with the clinicopathological features of patients were sought. (biomedcentral.com)
To assess the prognostic capacity of EHD1 for osteosarcomas, formalin-fixed, paraffin-embedded (FFPE) SCLC tumor tissues were collected from 57 osteosarcoma patients who underwent surgery between January 2011 and September 2015. (biomedcentral.com)
This study examines the influence of the heterogeneity of tumor proliferation on disease-free survival of patients with a breast carcinoma. (biomedcentral.com)
In the late 80s, they published an article in which they reported a low tumor regression rate (2.6-3.3%) in 1205 patients with metastatic cancer who underwent different types of active specific immunotherapy (ASI), and they suggest that AIET with specific chemotherapy or radiotherapy as the future of cancer immunotherapy. (wikipedia.org)
An evolving paradigm expanding the genetic basis of cancer suggests that developmental programs indelibly imprint restricted repertoires of homeostasis, forming the substrate for lineage-dependent tumor induction by deregulation of tissue-specific survival pathways. (jefferson.edu)
This was in patients whose tumors have high PD-L1 expression with no EGFR or ALK genomic tumor aberrations. (biospace.com)
In one study, Kathy Han, M.D., of the Princess Margaret Cancer Center at the University of Toronto, and colleagues found that liquid biopsy tests looking at persistent human papillomavirus (HPV) circulating tumor DNA (ctDNA) following chemoradiotherapy (CRT) can accurately identify inferior progression-free survival in patients with cervical cancer. (msdmanuals.com)
These patterns include an initial transient increase in tumor burden before response [ 4 , 5 ] and/or appearance of new lesions (NLs) in patients with responding baseline lesions. (medscape.com)

Disease-Free Survival: Endpoint for Adjuvant Therapy for Cancer? (medscape.com)
Cite this: Disease-Free Survival: Endpoint for Adjuvant Therapy for Cancer? (medscape.com)
The study's primary endpoint was PFS in addition to safety and overall survival. (bjh.be)
BUSINESS WIRE )--Positive results from the pivotal TROPION-Lung01 Phase III trial showed that datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the primary endpoint of progression-free survival (PFS) compared to docetaxel, the current standard of care, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior line of therapy. (businesswire.com)
this is an important endpoint for these patients, in whom rapid worsening of the disease can lead to worse symptoms and life-threatening situations. (prnewswire.com)
The primary endpoint was disease-free survival (DFS) at the interim analysis. (biospace.com)
Invasive disease-free survival was the primary endpoint of the study. (nepalnews.com)

Opdivo and Opdivo-based combinations have shown survival benefits in several earlier-stage and advanced cancers, including genitourinary tumors, and we are disappointed that the final analysis of CheckMate-914 Part A did not show this same benefit for the post-surgical treatment of patients with localized (kidney cancer)," Walker said. (curetoday.com)
Results: During a median follow-up duration of 24 months, two patients died of disease progression, and 11 experienced recurrent tumors (eight intrathoracic tumors, two distant metastasis, and one both types of recurrences). (iiarjournals.org)
According to the new trial results, treatment with atezolizumab following surgery and chemotherapy reduced the risk of disease recurrence or death by 34% in patients with stage 2-3A NSCLC whose tumors express PD-L1 ≥1%, compared with best supportive care. (globaloncologyacademy.org)
95% CI 0.72-1.13) and in patients with non-squamous tumors (HR 0.77 95% CI: 0.59-1.01), however, results did not reach statistical significance at the time of this data cut-off. (businesswire.com)
The improvement in progression-free survival observed with datopotamab deruxtecan, particularly in patients with non-squamous tumors, and the improved tolerability of this antibody drug conjugate compared to docetaxel, represent a meaningful advance for patients with lung cancer. (businesswire.com)
The benefit seen in patients with non-squamous tumors is particularly impressive and, coupled with the data from TROPION-Lung05, provides promising evidence that datopotamab deruxtecan may play an important role in treating patients with non-small cell lung cancer who currently have limited effective options following initial treatment. (businesswire.com)
We believe that this regimen may become the new standard of care, in part because it spares some patients from the use of local radiation to the bone marrow, the testes, or the central nervous system, which can cause life-altering side effects, such as sterilization, severe neuro-cognitive impairment, and brain tumors. (cancer.net)
The factors responsible for response to tamoxifen in 5% to 10% of patients with ERa-negative tumors are not clear. (lu.se)
ExperimentalDesign: We investigated ERh by immunohistochemistry in 353 stage II primary breast tumors from patients treated with 2 years adjuvant tamoxifen, and generated gene expres- sion profiles for a representative subset of 88 tumors. (lu.se)
Patients with tumors lacking ERa in general do not charges. (lu.se)
Purpose Treating solid tumors with cancer immunotherapy (CIT) can result in unconventional responses and overall survival (OS) benefits that are not adequately captured by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. (medscape.com)

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--April 3, 2006--Amgen (Nasdaq:AMGN), the world's largest biotechnology company, today announced pivotal Phase 3 results demonstrating that panitumumab significantly improved progression-free survival and disease control (response rate and stable disease) compared to best supportive care (BSC) in metastatic colorectal cancer patients who had failed standard chemotherapy. (amgen.com)
Panitumumab reduced the rate of disease progression by approximately half compared to best supportive care alone in these heavily pre-treated patients," said Marc Peeters, M.D., Ph.D., coordinator of Digestive Oncology Unit, University Hospital Ghent, and one of the study's lead investigators. (amgen.com)
A significantly higher proportion of patients were alive and free of disease progression on panitumumab at all of the scheduled time points through week 32. (amgen.com)
For example, after six months (week 24) approximately four times as many panitumumab-treated patients were alive and progression-free (18 percent versus five percent with BSC alone). (amgen.com)
Twice as many panitumumab-treated patients were alive and progression-free at week 32 (10 percent versus four percent with BSC alone). (amgen.com)
Panitumumab treatment also showed a clinical benefit in the patients crossing over from the BSC arm, despite their disease progression. (amgen.com)
Panitumumab improved progression-free survival and response rate regardless of the measured level or intensity of EGFr staining. (amgen.com)
Addition of Bruton's tyrosine kinase inhibitor ibrutinib to chemoimmunotherapy prolonged progression-free survival (PFS) in patients with untreated mantle cell lymphoma (MCL). (bjh.be)
The progression-free survival is substantially longer than the common treatment options used today, which is an important clinical advancement. (bjh.be)
The TROPION-Lung01 results demonstrate for the first time that an antibody drug conjugate can delay disease progression or death for longer than conventional chemotherapy in patients with advanced non-small cell lung cancer. (businesswire.com)
The pivotal Phase 3 study enrolled over 500 patients and demonstrated an improvement in progression free survival (PFS) for patients treated with YONDELIS. (prnewswire.com)
There was no statistically significant difference between the arms for progression-free survival. (aacr.org)
In addition, results presented earlier this week at the AACR Annual Meeting 2018 , which were simultaneously published in The New England Journal of Medicine and highlighted on this blog , showed that a combination of ipilimumab and nivolumab significantly improved the overall response rate and median progression-free survival among certain patients with non-small cell lung carcinoma, compared with standard-of-care chemotherapy. (aacr.org)
Progression-free and disease-specific survival were analyzed using the Kaplan Meyer test and compared using the log rank method. (lu.se)
The median progression-free survival was 7.7 months in the control arm and 12.6 months in the HIPEC arm (P = 0.020). (lu.se)
and three months after CRT) was independently associated with inferior progression-free survival. (msdmanuals.com)
imRECIST progression-free survival (PFS) did not count initial PD as an event if the subsequent scan showed disease control. (medscape.com)
Patterns of progression analysis revealed that patients who developed NLs without target lesion (TL) progression had a similar or shorter OS compared with patients with RECIST v1.1 TL progression. (medscape.com)
Conclusion Evaluation of PFS and patterns of response and progression revealed that allowance for TL reversion from PD per imRECIST may better identify patients with OS benefit. (medscape.com)
[ 9 ] Experience with immune checkpoint inhibitors has shown that the overall survival (OS) benefit with CIT is often not fully reflected in RECIST v1.1-based progression-free survival (PFS) or overall response rate (ORR). (medscape.com)

Cumulative disease-free survival (DFS) curves and overall survival (OS) curves were plotted using the Kaplan-Meier method, and the relationship between each of the variables and survival was assessed by log-rank tests using univariate analysis. (biomedcentral.com)
Kaplan-Meier curve for intensive care unit (ICU)-free survival. (cdc.gov)
Kaplan-Meier survival analysis was used to evaluate OS and DFS. (sages.org)
The log rank test on the Kaplan-Meier survival analysis revealed that there was no significant difference (p=0.591) in OS between TTE (median survival=52.6 months), MIE (median survival = 39.73 months) and THE (median survival=29.71 months). (sages.org)

That's what we generally call disease-free survival or event-free survival, and, of course, overall survival. (medscape.com)
This is called event-free survival. (cancer.net)
Among these patients, the 12-month event-free survival was 85%, compared to about 69% among the 116 participants who did not receive a stem cell transplant. (cancer.net)
Immune response to the PR1 vaccine was associated with an 8.7 month event-free survival compared with 2.4 months for non-responders. (algodonwineestates.com)
We did not expect dramatic responses in this clinical trial, and were pleasantly surprised to see the clinical responses and improved event-free survival' says Muzaffar Qazilbash, M.D., associate professor in M. D. Anderson's Department of Stem Cell Transplantation and Cellular Therapy. (algodonwineestates.com)

These findings come from a subset of patients within the phase 3 CheckMate-914 clinical trial, which is comparing post-surgical Opdivo plus Yervoy to Opdivo alone in patients with localized renal cell carcinoma (the most common type of kidney cancer) who underwent surgery to remove all or part of their kidney, and are at a high or moderate risk of relapse. (curetoday.com)
In this subset of patients with NSCLC, the median DFS was not yet reached for the atezolizumab arm, compared with a DFS of 35.3 months for the best supportive care arm. (globaloncologyacademy.org)
It is relatively easy to do with new technology and it means we can select a subset of patients who are likely to respond. (eurekalert.org)
While treatment uptake and survival outcomes were generally comparable across ethnicity and district health boards, dnMBC survival outcomes were considerably poorer than expected, earmarking this subset of patients with ABC for more in-depth research. (hindawi.com)

The open-label international trial included 1,886 patients with stage III colon cancer who underwent surgery for their cancer. (genengnews.com)
32 (40%) of patients who achieved CR/CRh underwent subsequent allogeneic HSCT. (nih.gov)
This study aimed to retrospectively evaluate the overall survival and disease-free survival outcomes of patients with HNC who received definitive IMRT with or without chemotherapy, planned with PET-CT.Materials and MethodsA total of 1,200 patients underwent treatment for HNC during the study period, from 1 January 2002 to 31 December 2010. (sagepub.com)
In total, 54 patients underwent oncological surgery, 129 were treated with radiotherapy, and 11 were treated with intravenous chemotherapy. (thieme-connect.com)
Objective: The objective of this study was to compare overall survival (OS) and disease free survival (DFS) among patients who underwent minimally invasive esophagectomy (MIE), trans thoracic esophagectomy (TTE) or trans hiatal esophagectomy (THE) for esophageal cancer. (sages.org)
Methods: A retrospective review of a prospectively maintained database was performed to identify patients who underwent an elective esophagectomy for esophageal cancer at a single institution between 1/1/2003 and 12/31/2008. (sages.org)
Results: One hundred and thirty three patients underwent esophagectomies during the study period of which 78 patients satisfied the study criteria. (sages.org)
During the follow-up, one patient was crossed over from the control arm and underwent cytoreduction and HIPEC for recurrent disease, after the assigned treatment was completed. (lu.se)

Materials and Methods: Data from sixty patients with stage I NSCLC who had undergone preoperative F-18 FDG PET-CT scanning were retrospectively analyzed. (iiarjournals.org)
Conclusion: For patients with stage I NSCLC treated with surgery, preoperative MTV parameters have a limited prognostic value for predicting DFS. (iiarjournals.org)
Initiating treatment without molecular profiling results may lead to metastatic NSCLC patients receiving therapies that provide suboptimal benefit. (ispor.org)
Adjuvant platinum-based chemotherapy is the current standard of care for patients with completely resected early-stage NSCLC who have a high risk for disease recurrence or relapse. (globaloncologyacademy.org)
In the broader population of all randomized stage 2-3A study participants with NSCLC, atezolizumab reduced the risk of disease recurrence or death by 21% following a median follow-up of 32.2 months. (globaloncologyacademy.org)
Datopotamab deruxtecan did not demonstrate a PFS benefit in patients with squamous NSCLC. (businesswire.com)
In January, Roche received Breakthrough Therapy Designation (BTD) from the FDA for a combination of Tecentriq and its investigational TIGIT blocker tiragolumab as first-line treatment of certain metastatic NSCLC patients. (biospace.com)

The aim of this study was to evaluate the relationship between the monocyte count assessed at diagnosis and disease-free survival and prognosis in patients with esophageal cancer. (researchsquare.com)
The effect of monocyte count assessed in the blood samples taken at the time of diagnosis prior to the initiation of the treatment on disease-free survival was investigated. (researchsquare.com)
Given that the monocyte count at the time of diagnosis dynamically reflects the systemic inflammatory response to cancer, studies often measure monocyte count at the time of diagnosis in their patients. (researchsquare.com)
In the present study, we aimed to investigate whether the monocyte count measured at the time of diagnosis can be used as a new prognostic biomarker in predicting disease-free survival in patients with esophageal cancer. (researchsquare.com)
Unfortunately, up to 20 % of stage I & II disease patients will develop recurrence within five years after diagnosis. (biomedcentral.com)
[ 5 , 6 ] Frequently, it is diagnosed only after a recurrence of disease in an area of bone where a diagnosis of fibrous dysplasia had previously been made. (medscape.com)
Of course, the risk of second malignancy is also a risk in adults, but the fact that the median age of adult cancer patients at diagnosis is in the seventh decade, that second malignancies after radiotherapy are uncommon in adults, and that they usually manifest 10-15 years after treatment make them less of a concern. (nature.com)
Although great progress has been made in diagnosis and treatment of CRC, global data demonstrated that the mortality was still unsatisfactory for CRC patients [ 2 ]. (biomedcentral.com)
Does exemestane therapy improve outcomes in patients who have breast cancer when begun two to three years after diagnosis? (aafp.org)
PAM is difficult to detect because the disease progresses rapidly so that diagnosis sometimes occurs after the patient dies. (cdc.gov)
Overall, the outlook for people who get this disease is poor, although early diagnosis and new treatments might increase the chances for survival. (cdc.gov)
This lack of standardization could pose challenges for clinicians and patients attempting to select a properly sized cuff to support hypertension diagnosis and management. (cdc.gov)
Most patients present with advanced/unresectable or metastatic disease at diagnosis, and no second-line regimen has demonstrated clinical benefit. (cdc.gov)
Patients with oral malignant melanoma often recall having an existing oral pigmentation months to years before diagnosis, and the condition may even have elicited prior comment from physicians or dentists. (medscape.com)
The International Agency for Research on Cancer (IARC) has published Patterns of care for women with breast cancer in Morocco: an assessment of breast cancer diagnosis, management, and survival in two leading oncology centres on the eve of the launch of the Global Breast Cancer Initiative by the World Health Organization (WHO). (who.int)
The study involved more than 2000 patients with breast cancer and documented the changing patterns of care over a decade, from 2008 to 2017, including temporal variations in breast cancer characteristics, the level of improvement in access to cancer diagnosis and treatment over time, the variations in practices related to breast cancer treatment, and the time trend of disease-free survival for these patients. (who.int)
Patients with a confirmed diagnosis of breast cancer who were registered at the two oncology centres be- tween 2008 and 2017 were included in the retrospective study. (who.int)

These benefits included significantly higher disease-free survival, and significantly higher overall survival, than the observation group. (eurekalert.org)
The researchers found that two dose dense regimens provided significantly higher disease-free survival rates than two regimens using conventional dosing, and that efficacy did not differ between the two dose dense regimens. (scienceblog.com)

A lymphoma vaccine uniquely tailored for each patient extends disease-free survival by 14 months, with signs of an even better response for patients with a specific biological marker, a team led by scientists at The University of Texas MD Anderson Cancer Center reported today in the online version of Journal of Clinical Oncology. (medicaldaily.com)
Findings from the CheckMate-914 trial showed that Opdivo plus Yervoy did not meet the study's main goal of disease-free survival for patients with localized renal cell carcinoma, a type of kidney cancer. (curetoday.com)
A study evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) - two immunotherapy agents - did not meet its main goal of disease-free survival (time a patient survives after treatment without signs or symptoms of their cancer) in certain patients with kidney cancer, according to Bristol Myers Squibb, the manufacturer of the drugs. (curetoday.com)
Even with notable progress in the treatment of metastatic (kidney cancer), there are still limited treatment options available for patients with localized disease," Dr. Dana Walker, vice president and development program lead of genitourinary cancers at Bristol Myers Squibb, said in a press release. (curetoday.com)
Currently, the average five-year survival rate for patients with metastatic or advanced kidney cancer is 14%, and just over half of patients with resectable, localized disease experience a five-year disease-free survival. (curetoday.com)
In this multi-national, open-label Phase 3 study, 463 patients with metastatic colorectal cancer who had failed standard chemotherapy, including oxaliplatin and irinotecan, were randomized to receive 6 mg/kg panitumumab plus BSC (n=231) every two weeks or BSC alone (n=232). (amgen.com)
The retrospective study included 145 patients with esophageal cancer who presented to Van Training and Research Hospital Medical Oncology outpatient clinic between January 2015 and September 2020. (researchsquare.com)
Our findings showed that monocyte count is a prognostic factor affecting disease-free survival in patients with esophageal cancer, regardless of histological subtype. (researchsquare.com)
Lymph node (LN) involvement represents the strongest prognostic factor in colon cancer patients. (biomedcentral.com)
Seventy-four stage I & II colon cancer patients were prospectively enrolled in the present study. (biomedcentral.com)
This study provides compelling evidence that ITC in stage I & II colon cancer patients are associated with significantly worse disease-free and overall survival. (biomedcentral.com)
Based on these data, the presence of ITC should be classified as a high risk factor in stage I & II colon cancer patients who might benefit from adjuvant chemotherapy. (biomedcentral.com)
It is assumed that complete surgical resection can be achieved in stage I & II colon cancer and therefore no further treatment is recommended for most of these patients. (biomedcentral.com)
However, the identification of factors predicting a worse survival in stage II colon cancer led the American Society of Clinical Oncology (ASCO) [ 3 - 5 ], the Nationonal Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) to define a collective of high-risk patients who may benefit from adjuvant chemotherapy. (biomedcentral.com)
There is rising evidence that colon cancer patients with micro-metastases will have a prognosis similar to patients with macro-metastases but little has been published about the prognostic impact of ITC. (biomedcentral.com)
There are clinical challenges related to adjuvant treatment in colorectal cancer (CRC) and novel molecular markers are needed for better risk stratification of patients. (frontiersin.org)
The article is " You're Cured Till You're Not: Should Disease-Free Survival Be Used as a Regulatory or Clinical End Point for Adjuvant Therapy of Cancer ? (medscape.com)
Number two is time free from cancer, ostensibly experiencing normal life for as long as possible. (medscape.com)
Again, by "cure," I mean getting back to a normal life and a life free from cancer presence and free from cancer recurrence. (medscape.com)
A real person, real life senior adult man hospital medical clinic outpatient colorectal cancer patient is sleeping in a reclining chair while intravenous IV drip chemotherapy medicine is administered through a surgically implanted subcutaneous chemo access port embedded into his upper chest. (bjh.be)
According to Michael Wang, MD, of MD Anderson Cancer Centre in Houston, "The SHINE study is the first international phase III trial to show a positive impact of ibrutinib combined with standard-of-care treatment in this disease. (bjh.be)
New Phase III trial data suggests giving colon cancer patients Roche's oral anticancer drug Xeloda in combination with intravenous oxaliplatin immediately after surgery boosts disease-free survival compared with combined postsurgery chemotherapy using 5-fluorouracil/leucovorin. (genengnews.com)
Disease-Free Survival: How Does Exercising Impact Colon Cancer? (coloncancerfoundation.org)
However, the extent to which a patient with colon cancer could improve their prognosis through exercising is something that was previously unknown, and is still being researched. (coloncancerfoundation.org)
In collaboration with the National Cancer Institute, two groups of patients with Stage III colon cancer (one of them being a placebo or control group) were randomly assigned to various community and academic centers throughout the U.S. and Canada to be evaluated during the duration of their treatment. (coloncancerfoundation.org)
If a patient with colorectal cancer picks up running as a new hobby because of this study and it makes them feel better in their day-to-day life, then that is a real-world influence of research studies. (coloncancerfoundation.org)
https://coloncancerfoundation.org/wp-content/uploads/2022/10/jzyhmzuvur474dyzuiga.jpg 389 600 [email protected] https://coloncancerfoundation.org/wp-content/uploads/2017/01/CCCF_Logo_Final_Color.png [email protected] 2023-10-24 09:36:52 2023-10-24 09:36:52 Disease-Free Survival: How Does Exercising Impact Colon Cancer? (coloncancerfoundation.org)
For non-muscle invasive bladder cancer (NMIBC), Bacille Calmette-Guerin (BCG) treatment is the standard immunotherapy for non-high risk NMIBC patients ( 3 ). (frontiersin.org)
However, most NMIBC patients will experience recurrence within 5 years, and a portion of patients will develop muscle-invasive bladder cancer (MIBC). (frontiersin.org)
Nevertheless, the 5-year survival rate for nonmetastatic MIBC patients (75% of newly diagnosed bladder cancer) is only 36% - 48% after first-line treatment, while the 5-year relative survival is 5% - 36% in metastatic MIBC ( 3 ). (frontiersin.org)
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. (ox.ac.uk)
METHODS: Individual patient data were pooled from 18 randomized phase III colon cancer adjuvant clinical trials. (ox.ac.uk)
The study involved a series of 368 patients from the François Baclesse Cancer Centre (Caen) treated for a breast carcinoma between 1991 and 1995, whitout neoadjuvant therapy and with a follow-up of more than 15 years. (biomedcentral.com)
Pivotal phase 3 data to be presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting found that atezolizumab (Tecentriq) extended disease-free survival (DFS) by more than one-third in patients with programmed death-ligand 1 (PD-L1)-positive, resectable early-stage lung cancer. (globaloncologyacademy.org)
The lung cancer space is in desperate need of a new adjuvant treatment option for the approximately 50% of patients who currently experience cancer recurrence following surgery. (globaloncologyacademy.org)
These results lay the groundwork for a new approach to the treatment of early-stage lung cancer and bring us closer to our goal of providing an effective and tailored treatment option for every person diagnosed with this disease. (globaloncologyacademy.org)
Pivotal Phase III Data at ASCO Show Genentech's Tecentriq Helps Certain People With Early Lung Cancer Live Significantly Longer Without Their Disease Returning [news release]. (globaloncologyacademy.org)
Two drugs, adriamycin and cytoxan, commonly used to treat breast cancer patients. (ucsfhealth.org)
Researchers who treated a group of post-surgery bladder cancer patients with the immunotherapy drug atezolizumab have found that patients whose blood contained circulating tumour DNA (ctDNA), responded very well to the treatment. (eurekalert.org)
The progress of the IMvigor 011 study will be watched closely by specialists for a greater assessment of the use of atezolizumab in bladder cancer patients. (eurekalert.org)
For patients with advanced non-small cell lung cancer, current standard of care second-line docetaxel is associated with limited benefit and substantial toxicity. (businesswire.com)
When the immune system is weaker then cancer evolves as a disease and starts growing. (wikipedia.org)
These two modalities affect not only the cancer affected cells, but also the normal cells Now in AIET, specific types of cells mainly the NK cells and T lymphocytes are isolated from the peripheral blood of the cancer patients (during remission in patients who undergo chemotherapy) by proven methods, expanded to 25-30 fold and activated and then reinfused back into the patient's body. (wikipedia.org)
There were 78 patients who had a bone marrow/stem cell transplant after receiving CAR T-cell therapy to destroy any remaining cancer cells. (cancer.net)
To put this study in context, the first child who received CAR T-cell therapy for B-ALL after multiple relapses has recently celebrated her 10-year cancer-free survival milestone, and we hope that our finding will result in many more such milestones. (cancer.net)
Your gift will help support our mission to end cancer and make a difference in the lives of our patients. (mdanderson.org)
Change the lives of cancer patients by giving your time and talent. (mdanderson.org)
A new clinical trial has shown that reducing the interval between successive doses of a commonly used chemotherapy regimen improves survival in women whose breast cancer has spread to the lymph nodes. (scienceblog.com)
While previous research has evaluated the use of various forms of "dose dense" chemotherapy, this is the first major controlled study to show a clear survival benefit for women with node-positive breast cancer. (scienceblog.com)
With the availability of new drugs to control one of the most serious side effects of chemotherapy administration, we can further increase the chances of survival for women with breast cancer. (scienceblog.com)
If confirmed and extended by additional research, this finding could positively affect the care of thousands of patients throughout the world with breast cancer and perhaps, eventually, other diseases. (scienceblog.com)
We're excited by the clinical benefit adjuvant Tecentriq may bring to lung cancer patients, particularly in the PD-L1-positive population. (biospace.com)
We look forward to advancing our tiragolumab development program, which includes chemotherapy-free combinations and trials in early stages of disease across multiple cancer types with high unmet need. (biospace.com)
Early this week, the U.S. Food and Drug Administration (FDA) approved a combination immunotherapy regimen for treating certain patients newly diagnosed with advanced renal cell carcinoma, the most common form of kidney cancer . (aacr.org)
A study found that patients with early hormone-receptor (HR) positive/HER2 negative breast cancer had a significant advantage in invasive disease-free survival when ribociclib, a targeted therapy medicine, was added to hormone treatment. (nepalnews.com)
Researchers from UCLA Jonsson Comprehensive Cancer Centre found that individuals who received the combination therapy had much longer invasive disease-free life than those who received hormone therapy alone, regardless of whether the cancer had progressed to the lymph nodes. (nepalnews.com)
The findings show this combination is a treatment of choice for patients with stage 2 or stage 3 HR positive/HER2 negative breast cancer. (nepalnews.com)
HR-positive/HER2-negative breast cancer is the most common subtype of the disease and accounts for nearly 70% of breast cancer cases in the Unites States. (nepalnews.com)
Previously, Slamon and researchers at the Jonsson Cancer Center demonstrated that adding ribociclib, a cyclin-dependent kinase inhibitor, to the standard hormone therapy improves overall survival in both premenopausal and postmenopausal women with metastatic HR positive/HER2 negative breast cancer. (nepalnews.com)
The clinical trial, called NATALEE, involved 5101 patients with stage 2 or stage 3 early HR positive/HER2 negative breast cancer. (nepalnews.com)
The Auckland Advanced Breast Cancer Review (AABC) was a review of patients diagnosed with advanced inoperable/metastatic breast cancer (ABC) within the Auckland region of New Zealand, commissioned in response to a Breast Cancer Registry report (BCFNZR) that showed poor and inequitable survival outcomes. (hindawi.com)
In this retrospective study, patients living within the Auckland region, diagnosed with ABC between the 1st January 2013 to the 31st December 2015 were identified from the Breast Cancer Registry. (hindawi.com)
Approximately 300 patients are diagnosed with advanced breast cancer (ABC) in New Zealand (NZ) annually. (hindawi.com)
In a recent Global Burden of Disease report, breast cancer retained its position as one of the top ten leading causes of death in the country [ 2 ]. (hindawi.com)
Central to the report was a survival analysis of ABC cases registered in the Breast Cancer Foundation National Registry (BCR) between the year 2000-2015. (hindawi.com)
Interestingly, the metastasis free interval (mFI: 30 months) amongst patients who developed metastatic relapse after early breast cancer was similar to international standards. (hindawi.com)
Drug-eluting beads trans-arterial chemoembolization for leiomyosarcoma, liver metastases from colorectal cancer, and for primary and liver-dominant metastatic disease of the liver. (aetna.com)
Purpose: Endocrine therapies, such as tamoxifen, are commonly given to most patients with estrogen receptor (ERa) ^ positive breast carcinoma but are not indicated for persons with ERa-negative cancer. (lu.se)
Conclusion: Expression of ERh is an independent marker for favorable prognosis after adjuvant tamoxifen treatment in ERa-negative breast cancer patients and involves a gene expression program distinct from ERa. (lu.se)
The authors assessed two liquid biopsy assays, including a digital polymerase chain reaction test and a sequencing-based assay (HPV-seq) that enables highly sensitive detection and accurate HPV genotyping from baseline plasma cell-free DNA, the main cause of cervical cancer. (msdmanuals.com)
Seventy patients from four centers who were diagnosed with HPV-positive cervical cancer and treated with CRT were enrolled in the study and followed for just over two years. (msdmanuals.com)
The researchers found that both tests were equally effective in identifying minimal residual disease among patients with cervical cancer who completed CRT. (msdmanuals.com)
HPV ctDNA testing can identify, as early as at the end of CRT, cervical cancer patients at high risk of recurrence or future treatment intensification trials," Han said. (msdmanuals.com)
As part of the FABREC study, Julia Wong, M.D., of the Dana-Farber Brigham Cancer Center in Boston, and colleagues found that patients with breast cancer who undergo implant-based reconstruction immediately following mastectomy and receive a shorter course of radiation therapy experience similar outcomes to patients who receive a conventional course of radiation. (msdmanuals.com)
In the multi-institutional phase II study TransTasman Radiation Oncology Group FASTRACK II, Shankar Siva, Ph.D., of the Peter MacCallum Cancer Centre and the University of Melbourne in Australia, and colleagues found that high-dose radiation is an effective treatment option for older patients with kidney cancer who are ineligible for surgery. (msdmanuals.com)
FASTRACK II is the first multicenter clinical trial of a nonoperative therapy for patients with primary kidney cancer. (msdmanuals.com)
The investigators observed 100 percent local control and 100 percent cancer-specific survival. (msdmanuals.com)
Patients and Methods Atezolizumab data from clinical trials in non-small-cell lung cancer, metastatic urothelial carcinoma, renal cell carcinoma, and melanoma were evaluated. (medscape.com)
Phase I/II study with the HER1 therapeutic vaccine in patients with asymptomatic or minimally symptomatic hormonal castration-resistant prostate cancer or metastatic colon cancer. (who.int)
They were on abstraction of data from the case · to document the delays across chosen because they provide com- record files of patients with breast the breast cancer care contin- prehensive cancer care and have cancer registered at CM-VI and INO. (who.int)
For a few patients, the pathol- targeted therapy, and pal iative care), in the case records at the two ogy report confirming cancer diag- fol ow-up, and vital status data. (who.int)
2.3 Selection of patients received cancer-directed treatment cancer in Morocco. (who.int)

The main goal of the study was determining disease-free survival, with secondary goals of overall survival (time from treatment until death of any cause) and incidence of side effects. (curetoday.com)
In these patients, panitumumab treatment resulted in a nine percent partial response and 32 percent stable disease, as well as one complete response. (amgen.com)
Adjuvant treatment is usually reserved to stage III disease. (biomedcentral.com)
The patient benefit of an adjuvant treatment in this subgroup, however, remains a matter of debate [ 7 ]. (biomedcentral.com)
There is limited literature comparing patients with results prior to treatment initiation and received recommended therapy vs. those initiating treatment without results or did not receive recommended therapy. (ispor.org)
This retrospective analysis identified patients (≥18 years) in the ConcertAI Oncology Dataset initiating first line (1L) treatment for non-squamous mNSCLC diagnosed 01/01/2015 or later. (ispor.org)
Patients with mNSCLC may benefit from waiting for results prior to initiating 1L treatment. (ispor.org)
These findings could improve the discrimination of patients who would benefit from adjuvant treatment. (frontiersin.org)
This result supported that FLs monotherapy is the preferred treatment for a patient with stage II disease, even if the routine administration of adjuvant therapy is not recommended in these patients. (frontiersin.org)
There is so much discussion in the adjuvant world about not making treatment decisions based on anything but overall survival. (medscape.com)
Patients with mantle cell lymphoma are often very old, and their inclusion in clinical studies can help design beneficial and tolerable treatment regimens. (bjh.be)
Patients' METs were evaluated throughout their chemotherapy treatments as well as six months after treatment completion. (coloncancerfoundation.org)
Further assessment of blinatumomab treatment earlier in the course of the disease and in combination with other treatment approaches is warranted. (nih.gov)
Incidence of distance metastatic disease and additional cancers were also studied.ResultsMedian follow-up from treatment initiation was 26·4 months (range 1·2-84·7 months). (sagepub.com)
There was an overall low incidence of distant metastatic disease (3·07%) and additional cancers (8·05%).ConclusionOverall and disease-free survival outcomes of a large cohort of HNC patients treated with definitive IMRT radiotherapy following treatment planning with PET-CT shows a similar high level of disease control and mortality rate as previously published outcome studies of shorter terms and/or smaller numbers of patients. (sagepub.com)
However, the researchers said this treatment only provides a 4% to 5% improvement in 5-year survival compared with observation. (globaloncologyacademy.org)
The replacement marrow may be taken from the patient before treatment or may be donated by another person. (ucsfhealth.org)
https://zhangzhiqiao8.shinyapps.io/Artificial_Intelligence_Survival_Prediction_for_CRC_B1005_1/ , which was valuable for individualized treatment decision before surgery. (biomedcentral.com)
The research was part of a larger Phase III trial, IMvigor010, which looked at whether giving atezolizumab for up to one year to patients following bladder removal surgery improved the patients' survival prospects, compared to a group that received no further treatment after surgery but placed in an observation group. (eurekalert.org)
Part of that trial involved patients' levels of ctDNA being measured after surgery, and during further treatment or observation. (eurekalert.org)
In addition, the researchers also found that patients that were ctDNA positive, but subsequently changed to became ctDNA negative after treatment with atezolizumab, ultimately had a particularly good prognosis. (eurekalert.org)
He continued: "If we can prove that consequent drug activity is linked to ctDNA status, and that high-risk patients will benefit, that could in time change the standard treatment pathway - and ultimately bring down the average cost of ctDNA analysis. (eurekalert.org)
But these robust findings show that that ctDNA has great potential as a sophisticated tool to monitor patients and choose their most effective treatment. (eurekalert.org)
In an article published in the Journal of Clinical Oncology , the study authors reported that 99% of the 194 patients in the clinical trial had undetectable disease after the treatment. (cancer.net)
Across all 194 patients with high-risk ALL, 192 (99%) had a complete remission after the treatment. (cancer.net)
Oct. 23, 2015 /PRNewswire/ -- Janssen Biotech, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved YONDELIS ® (trabectedin) for the treatment of patients with unresectable (unable to be removed with surgery) or metastatic liposarcoma (LPS) or leiomyosarcoma (LMS) who received a prior anthracycline-containing regimen. (prnewswire.com)
We are proud that our Phase 3 study is the largest ever conducted in this patient population and we're delighted that patients in the U.S. can now benefit from the treatment. (prnewswire.com)
Cases were evaluated and discussed on an individual basis at the MDT meetings, and, after a consensus regarding delaying or scheduling treatment, patients were scheduled according to the risk of postponing the procedures. (thieme-connect.com)
Patients were randomized into two arms: 2549 were randomized to the combination treatment and 2552 to the hormone therapy alone. (nepalnews.com)
Demographic, diagnostic, treatment, and survival data were extracted from electronic records for statistical analysis. (hindawi.com)
Despite improvements in treatment options and survival outcomes in recent years, NZ ABC mortality rates continue to exceed the OECD average [ 1 ]. (hindawi.com)
After randomization, four patients in the HIPEC arm and six in the control arm were not treated using the intended therapy, one patient because of withdrawal, one because of a life-threatening other malignant disease and the others because of progressive disease before initiation of the treatment. (lu.se)
Patients who have often gone through months of treatment prior to radiation, can safely undergo three instead of five weeks of postmastectomy radiation and have similar outcomes," Wong said. (msdmanuals.com)
In this study, the authors enrolled patients who were unable or unwilling to undergo surgery and tested a novel therapy -- stereotactic ablative body radiotherapy (SABR) -- as a curative treatment option. (msdmanuals.com)
Treatment protocols for soft tissue sarcoma are provided below, including recommendations for low- and high-grade soft tissue sarcomas, for metastatic disease, and for soft tissue sarcomas with special histologies. (medscape.com)
Patients were selected for features associated with increased transmissibility: smear (+) sputum, coughing, lung cavitation, and recent initiation of standardized treatment, and remained on the ward 2 weeks before being replaced. (cdc.gov)

But this is the first time we've been able to show that with immunotherapy we can actually change the course of the disease depending on a patient's ctDNA status. (eurekalert.org)
Immunotherapy works best for low level of disease,' Qazilbash says. (algodonwineestates.com)
After a median follow-up of 25.2 months, the 18-month survival rate was 77 percent for the immunotherapy combination arm compared with 60 percent for the sunitinib arm. (aacr.org)
In addition, at that time, it was not possible to estimate the median overall survival among those receiving the immunotherapy combination, whereas it was estimated to be 25.9 months among those who received sunitinib. (aacr.org)

The discussion that has gone on in oncology meetings and forums all over the world is this focus of overall survival vs disease-free survival. (medscape.com)
The records of eligible patients using surgery, chemotherapy, registered during a 2-month period A data col ection form (Annex 1) was radiotherapy, hormone thera- of each year, starting from 2008 and designed to reconstruct the trajecto- py, and targeted therapy at the ending in 2017, were scanned for in- ry of patients in the health-care sys- two oncology centres and any formation. (who.int)

Policies and legislation that promote more equitable environments and reduce the burden of poverty in our society may help to alleviate the disparities we see in outcomes of patients with IPF. (medicalxpress.com)
Overall and disease-free survival outcomes of patients receiving intensity-modulated radiation. (sagepub.com)

Of 238 patients, 94 (39.5%) were in cohort A. Overall, 60.9% were ≥65 years, 51.3% male, and 77.7% white. (ispor.org)
I was surprised that we were able to find a significant impact of neighborhood-level disadvantage on survival in our relatively small cohort of patients with IPF. (medicalxpress.com)
Aim To investigate the role of ERβ and its association with hormone status and lifestyle indicators in a female cohort of patients with CRC. (lu.se)

Study investigators also reported that panitumumab significantly improved disease control versus BSC alone (36 percent versus 10 percent, respectively), as measured by response rate and stable disease. (amgen.com)
Our preliminary data from our single center study at the University of Pittsburgh indicates that neighborhood-level disadvantage may be associated with increased mortality and reduced odds of receiving a lung transplant in patients with IPF," stated Dr. Goobie, study author. (medicalxpress.com)
To design a simple and reproducible classifier predicting the overall survival (OS) of patients with acute myeloid leukemia (AML) ≥60 years of age treated with 7 + 3, we sequenced 37 genes in 471 patients from the ALFA1200 (Acute Leukemia French Association) study (median age, 68 years). (nih.gov)
The study population included a total of 270 stage II-III CRC patients treated with adjuvant FL with (FL + OXA, n = 119) or without oxaliplatin (FL, n = 151). (frontiersin.org)
Study evaluated the drug in combination with oxaliplatin in stage III patients. (genengnews.com)
In a multicentre, single-arm, open-label phase 2 study, we enrolled adult patients with Philadelphia-chromosome-negative, primary refractory or relapsed (first relapse within 12 months of first remission, relapse within 12 months after allogeneic haemopoietic stem-cell transplantation [HSCT], or no response to or relapse after first salvage therapy or beyond) leukaemia. (nih.gov)
The current study identified twenty prognostic immune genes for CRC patients and constructed an immune-related regulatory network. (biomedcentral.com)
Results from a recent study from China showed that a new approach to chimeric antigen receptor (CAR) T-cell therapy was able to put B-cell acute lymphoblastic leukemia (ALL) into remission in many children with high-risk disease. (cancer.net)
The approval was based on recently published clinical efficacy and safety data from the Phase 3, randomized, open-label, controlled study (ET743-SAR-3007), which evaluated YONDELIS versus the chemotherapy agent dacarbazine, in patients with unresectable or metastatic LPS or LMS previously treated with an anthracycline and at least one additional chemotherapy regimen. (prnewswire.com)
In addition to improved disease-free survival, the study indicated that dose dense chemotherapy may also lead to higher overall survival rates. (scienceblog.com)
Smartphone pictures of post-surgical wounds taken by patients and then assessed by clinicians can help with the early identification of infections, a study has found. (ed.ac.uk)
A study led by the Universities of Edinburgh and Birmingham has been awarded the Guinness World Record title for the world's largest scientific collaboration, involving over 140,000 patients in 116 countries. (ed.ac.uk)
The median duration on study follow-up was 34 months, with three-year and two-year duration of ribociclib completed by 20% and 57% patients respectively. (nepalnews.com)
Of the 388 patients that met inclusion criteria for this study, median overall survival (medOS) was 18.9 months in the total population, with no difference between patients with de novo metastatic disease (dnMBC -18.9 m) and recurrent metastatic disease (rMBC -18.7 m). (hindawi.com)
The aim of the present study was to eluci- date the biology and prognostic role of the second ER, ERh, in patients treated with adjuvant tamoxifen. (lu.se)
In the original study, four patients were excluded-two because of no eligible histology/pathology and two because of major protocol. (lu.se)
The objective of the study is to evaluate CT-LeSc long-term prognostic value in patients with suspected coronary artery disease (CAD). (who.int)
This was a phase 2 study evaluating the efficacy and safety of regorafenib in patients who had advanced/unresectable or metastatic disease after receiving standard therapy. (cdc.gov)
Patients of childbearing age who are not using an adequate method of contraception (intrauterine devices, hormonal contraceptives, barrier methods or surgical sterilization) prior to their inclusion in the study. (who.int)
All patients included in the study will be treated with the HER1 vaccine. (who.int)
Methods: For each 2-3 month study, a series of 6 consenting MDR/XDR patients simultaneously occupied the Airborne Infections Research facility ward at the Mpumalanga Provincial MDR Referral Hospital in Witbank, South Africa. (cdc.gov)

Single-agent blinatumomab showed antileukaemia activity in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia characterised by negative prognostic factors. (nih.gov)
In the analysis of prognostic factors, disease free survival was used as the end point. (biomedcentral.com)

The process of getting patients onto a clinical trial, or the number of patients planned for a given trial. (ucsfhealth.org)
The results from the clinical trial have immediate implications for patients," said Slamon. (nepalnews.com)

Table 1 Univariate Analysis of Disease Free Survival - 368 Eligible Patients. (biomedcentral.com)

In this talk, I will describe some endoscopic microscopy techniques developed, including optical coherence tomography (OCT), optical coherence microscopy (OCM), and confocal microscopy (CM) and will discuss how these methods can potentially impact patient care. (stanford.edu)
Patients and Methods: For all patients still alive, the follow-up was updated until 2007. (lu.se)
METHODS AND RESULTS: Single-center prospective registry including 1304 consecutive patients undergoing coronary CT angiography for suspected CAD. (who.int)
Methods Tissue microarrays of primary CRC tumour samples from 320 female patients were conducted with a monoclonal anti-ERβ antibody. (lu.se)

Our aim was to integrate our previously reported clinical-genetic prognostic score with new immunogenetic markers of 5-year disease-free survival (DFS) to evaluate the recurrence risk stratification before fluoropyrimidine (FL)-based adjuvant therapy. (frontiersin.org)
First, they highlight a fundamental difference in the goals of care and realistic objectives for patients receiving therapy for metastatic, generally not curable cancers vs those receiving adjuvant therapy for potentially curable cancers. (medscape.com)

An interim analysis of overall survival between the two groups was similar. (amgen.com)
Although the trial found no significant difference in overall survival between the two groups in the intention-to-treat population, researchers noticed that a subgroup of patients who were ctDNA positive showed a marked improvement when they were given atezolizumab. (eurekalert.org)

The data showed a statistically significant improvement in the risk of invasive disease in favour of the combination arm. (nepalnews.com)
No statistically significant differences in medOS was found amongst Maori (16.2 m), Pacific People (17.3 m), and NZ European (18.9 m) or when patients were stratified according domicile district health board. (hindawi.com)

The aim of the present article is to report our experience throughout the Covid-19 pandemic treating patients with urological neoplasms at a high-volume center. (thieme-connect.com)

The FDA granted Welireg a priority review after it showed promising outcomes for patients with pretreated advanced renal cell carcinoma. (curetoday.com)
One prediction model developed by the International Metastatic Renal-Cell Carcinoma Database Consortium classifies patients based on the presence or absence of six risk factors. (aacr.org)

This prognostic model could discriminate high risk patients with poor prognosis from low risk patients with favorable prognosis. (biomedcentral.com)
Professor Gschwend, Chairman of the Department of Urology at the Technical University of Munich, said: "We already knew that patients who are ctDNA positive have a poor prognosis compared to those who are ctDNA negative. (eurekalert.org)

Disease-free survival was 17.3 months (95% CI: 8.4-26.2) in patients with a monocyte count ≥515/μL as opposed to 38.5 months (95% CI: 28. (researchsquare.com)
The median OS time of patients with high expression of EHD1 was 46.8 months (95% CI, 29.8-63.8 months), and the median OS time of patients with low expression of EHD1 was 58.8 months (95% CI, 31.6-86.0 months). (biomedcentral.com)
Median PFS was 4.4 months in patients treated with datopotamab deruxtecan versus 3.7 with docetaxel. (businesswire.com)
At 12 months, nearly 74% had no signs or symptoms of the disease. (cancer.net)
Results A total of 194 patients were assessed by the multidisciplinary team and finally treated, with median follow-up of 4 (interquartile range [IQR]: 2.75 to 6) months. (thieme-connect.com)
The composite median overall survival (medOS) of women in NZ with ABC was 16 months, while one-year and five-year survival rates were documented at 46% and 12%, respectively. (hindawi.com)
This inequity was reflected in the BCFNZR, where Maori had the poorest survival outcomes amongst patients with ABC compared to all other ethnicities in NZ, with a medOS of only 12.8 months. (hindawi.com)
The median disease-specific survival was 12.6 months in the control arm and 22.2 months in the HIPEC arm (P = 0.028). (lu.se)
The patient was followed up for the next 12 months without any recurrence of disease. (cdc.gov)
Results The best overall response was 1% to 2% greater, the disease control rate was 8% to 13% greater, and the median PFS was 0.5 to 1.5 months longer per imRECIST versus RECIST v1.1. (medscape.com)
ary for 2008, was shifted to the next The form col ected basic personal in- · to document the disease-free 2 months every year, and restarted in formation (age, education level, mar- survival (DFS) of patients with January and February after 6 years. (who.int)

People are more likely to develop IPF or other forms of interstitial lung disease (ILD) if they have worked in an occupation that has significant exposure to airborne materials. (medicalxpress.com)

Another major point to be addressed about this killer disease is the relapse rate which is very high. (wikipedia.org)

The conclusion of this article by Sobrero and colleagues is that, in the adjuvant and neoadjuvant setting, disease-free survival is the primary variable. (medscape.com)
The primary hypothesis was that disease-free survival (DFS), with 3 years of follow-up, is an appropriate primary end point to replace OS with 5 years of follow-up. (ox.ac.uk)
The incidence and timing of locoregional recurrence, distant metastatic disease, new primary malignancies and death were evaluated retrospectively. (sagepub.com)
The primary outcome was disease-free survival. (aafp.org)
Primary amebic meningoencephalitis (PAM) is a disease of the central nervous system. (cdc.gov)

A combination of surgery and chemotherapy results in the long-term survival of approximately 60-70% of osteosarcoma patients [ 3 ]. (biomedcentral.com)
With 500 participants, the trial will further evaluate the use of ctDNA sampling, and will compare atezolizumab against placebo in only ctDNA-positive patients, post-surgery. (eurekalert.org)
all patients answered the Centers for Disease Control and Prevention (CDC) Covid-19 self-screening questionnaire prior to surgery. (thieme-connect.com)
DFS was defined as the interval between surgery and recurrence in the form of local recurrence or metastatic disease. (sages.org)

CONCLUSION: In patients treated on phase III adjuvant colon clinical trials, DFS and OS are highly correlated, both within patients and across trials. (ox.ac.uk)
Conclusion: With 90% of all events having taken place up to this time, this randomized trial shows that cytoreduction followed by HIPEC does significantly add survival time to patients affected by peritoneal carcinomatosis of colorectal origin. (lu.se)
Conclusion Elevated ERβ expression is independently associated with a better prognosis and hormone status but not lifestyle indicators in female CRC patients. (lu.se)

The other corollary of this is where cure is a realistic goal of therapy - such as when you are considering patients for adjuvant and neoadjuvant therapy in lung cancers - there is a different metric and tradeoff between toxicity and benefit. (medscape.com)

With a disease like IPF, which has a very high mortality, we are more able to demonstrate the substantial impact that these neighborhood-level factors can have on survival and transplant outcomes. (medicalxpress.com)
MIBC is an aggressive disease associated with high morbidity and mortality, and life prolonging therapies include radical cystectomy, chemotherapy, radiotherapy, and immune checkpoint inhibitors ( 4 ). (frontiersin.org)
From the patient's point of view, mortality risk predicted percentage for an individual patient is more valuable and important than that for a special group. (biomedcentral.com)
Transfusion-dependent patients with thalassemia major(TM) develop iron overload which leads to damage of the liver, heart, and endocrine organs and related morbidity and mortality ( 1 1. (scielo.br)
Iron chelation therapy with desferrioxamine (DFO), available since the late 1960s and the most widely used iron chelator, decreased iron overload-related complications and mortality rate of patients with TM ( 4 4. (scielo.br)

However, the long-term survival rate remained low and 50% of patients did not reach 35 years of age ( 7 7. (scielo.br)

Adding oxaliplatin (OXA) to therapy based on FLs (5-FU and capecitabine) further improves the disease-free (DFS) and OS rates in patients with stage III disease. (frontiersin.org)

Figure 1 Survival of acute myeloid leukemia patients (without palliative) according to 1% CD34+CD38- cut-off. (wjgnet.com)
5. Acute or chronic decompensated lung diseases. (who.int)

A total of 915 patients from CM-VI and 1205 patients from INO were included in the analysis. (who.int)

Patients were then instructed to report the average weekly time that they spent exercising. (coloncancerfoundation.org)
Overall and disease-free survival (survival to time of first recurrence) were determined by the life table method. (sagepub.com)
Follow-up will continue with planned analyses of DFS in the overall intent-to-treat population, including stage 1B patients who did not cross the threshold at the time of analysis. (globaloncologyacademy.org)
It involves tumour specific gene sequencing for every patient, so is time-consuming and, at present, relatively expensive. (eurekalert.org)
Only two patients had Covid-19 confirmed by real-time polymerase chain reaction (RT-PCR). (thieme-connect.com)
They also plan to follow overall survival (OS) data, which was immature at the time of analysis. (biospace.com)
At the time of this analysis, 189 people in the ribociclib group experienced an invasive disease-free survival event, compared to 237 people in the hormone therapy alone group. (nepalnews.com)
Patients provided blood samples at three time points. (msdmanuals.com)
It is also seen more frequently with advancing patient age, presumably because of increased exposure to dental procedures over time. (medscape.com)
Some patients demonstrate a long-term inflammatory response, with small, discolored papules produced, and in those who exhibit a strong macrophage response, the discolored patch can enlarge over time as the macrophages engulf the foreign material and attempt to move it out of the area. (medscape.com)

I am looking forward to validating these results in a larger and more diverse population of patients with IPF and other forms of fibrotic ILD," stated Dr. Goobie. (medicalxpress.com)
However, the results from the QUASAR and MOSAIC trials demonstrated no further benefit when adding OXA to 5-FU in stage II patients, even those at high risk. (frontiersin.org)
Results also showed a confirmed objective response rate (ORR) of 26.4% in patients treated with datopotamab deruxtecan compared to an ORR of 12.8% with docetaxel. (businesswire.com)
Currently there are three iron chelating agents available for continuous use in patients with thalassemia on regular transfusions (desferrioxamine, deferiprone, and deferasirox) providing good results in reducing cardiac, hepatic and endocrine toxicity. (scielo.br)
Select "Patients / Caregivers / Public" or "Researchers / Professionals" to filter your results. (aacr.org)
These results should change how we evaluate and treat patients. (nepalnews.com)

The stable disease rate was 28 percent with panitumumab versus 10 percent with BSC alone. (amgen.com)
Modifications to imRECIST versus RECIST v1.1 included allowance for best overall response after progressive disease (PD) and changes in PD definitions per new lesions (NLs) and nontarget lesions. (medscape.com)
OS was evaluated using conditional landmarks in patients whose PFS differed by imRECIST versus RECIST v1.1. (medscape.com)

These social determinants of health impact the outcome of many chronic diseases. (medicalxpress.com)

In patients with anti-panitumumab antibodies, there was no impact on efficacy, safety and pharmacokinetics. (amgen.com)
Towards this, the SHINE trial has investigated the efficacy and safety of adding ibrutinib to the standard of care for MCL patients. (bjh.be)
Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. (scielo.br)
In addition, according to the FDA statement, the combination did not show efficacy for patients with favorable-risk disease. (aacr.org)
Upper room UVGI efficacy was determined by comparing the proportion of infected animals in each chamber and using survival analysis. (cdc.gov)

Centers for Disease Control and Prevention. (cdc.gov)
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. (cdc.gov)
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website. (cdc.gov)

Anatomy10

Organisms7

Diseases56

Chemicals and Drugs59

Analytical, Diagnostic and Therapeutic Techniques and Equipment78

Phenomena and Processes38

Disciplines and Occupations1

Anthropology, Education, Sociology and Social Phenomena1

Information Science11

Named Groups3

Health Care35

Geographicals2

Tumor22

Endpoint7

Tumors11

Progression20

Kaplan-Meier4

Event-free survival5

Subset of patients4

Underwent8

NSCLC7

Diagnosis17

Significantly higher2

Cancer82

Treatment36

Immunotherapy4

Oncology2

Outcomes of patients2

Cohort3

Study21

Prognostic factors2

Clinical trial2

Analysis of Disease Free Survival1

Methods4

Adjuvant therapy2

Overall survival between the two groups2

Statistically significant2

Neoplasms1

Renal cell carc2

Poor prognosis2

Months11

Interstitial lung di1

Relapse1

Primary5

Surgery4

Conclusion3

Cancers1

Mortality5

Long-term survival rate1

Improves1

Acute2

1205 patients1

Time10

Results6

Versus3

Outcome1

Efficacy5

Centers3